Recent Updates
Recently added Catalysts
SI Positive Sentiment

Catalyst OrthoScience Announces Settlement of Patent Litigation with Shoulder Innovations

Wednesday, September 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Catalyst OrthoScience has announced a settlement agreement with Shoulder Innovations to resolve all pending patent litigation. This agreement fully resolves the dispute between the two companies, although the specific terms remain confidential. The settlement allows Catalyst to continue its focus on innovating shoulder arthroplasty technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Settlement resolves all pending patent litigation.
  • Confidential terms may indicate a favorable outcome for both parties.
  • Catalyst OrthoScience continues to focus on innovation in shoulder arthroplasty.

Full Press Release Details

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies. The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential. “Inte

Frequently Asked Questions

What was the outcome of the litigation between Catalyst and Shoulder Innovations?

Catalyst OrthoScience and Shoulder Innovations reached a settlement to resolve all pending patent litigation.

Are the terms of the settlement agreement public?

No, the terms of the settlement agreement are confidential.

What does Catalyst OrthoScience focus on?

Catalyst OrthoScience focuses on innovating shoulder arthroplasty through simplified, surgeon-focused technology.

ShareAdd on Google
Tags: SI Viatris Investor Conferences Healthcare Catalyst OrthoScience Shoulder Innovations patent litigation medical device technology shoulder arthroplasty
Last updated: Sep 9, 2026

Biotech snapshot

Cash runway
$99M liquidity · $2M/mo burn
~39 mo
Minimal dilution risk